Navigation Links
Approximately One-Third of MS Patients Experiencing Relapses Do Not Adequately Respond to Traditional Corticosteroid Therapy, According to New Data Presented at the 5th Joint Congress of the European and Americas Committees for Treatment and Researc
Date:10/21/2011

AMSTERDAM, Oct. 21, 2011 /PRNewswire/ -- On October 21 at the 5th Joint Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), results were presented from a survey conducted by NARCOMS which found that about one-third of patients experiencing MS relapses do not adequately respond to corticosteroid treatment.  The survey included over 2,000 patients with MS who had experienced relapses and were treated with either intravenous (IV) or oral corticosteroids.  Corticosteroids are generally considered to be first-line therapy for MS relapses requiring therapy by most neurologists.

Of 1,122 MS patients surveyed who had been treated with IV steroids for their relapses, 31% reported no change or a worsening of relapse symptoms following treatment.  Of 894 MS patients treated with oral steroids for relapses, 39% reported no change or a worsening of symptoms following treatment.

"This NARCOMS survey helps to further our understanding about the experiences and perspectives of patients who are suffering from MS relapses," said Ruth Ann Marrie, MD, PhD, Director of the Multiple Sclerosis Clinic at the Health Sciences Centre, Winnipeg, Manitoba, Canada and NARCOMS representative.  "We hope that such information can be helpful to both physicians and patients in the management of MS."

This survey was one of an ongoing series of patient surveys independently conducted by NARCOMS on a variety of important topics related to MS patient care.  NARCOMS is a non-profit project of the Consortium of Multiple Sclerosis Centers and operates the largest North American MS patient self-report registry, with the ultimate goal of improving research, treatment and education.

"These findings provide a major step forward in the understanding of how MS patients who are suffering relapses view their experience with corticosteroid treatment, which has been the most widely-used first-line relapse treatment for nearly three decades," said Steve Cartt, Executive Vice President and Chief Business Officer of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR). "The data confirm the need for additional treatment options for MS relapses.  For many of these patients who do not respond adequately to corticosteroid treatment, Acthar can be a viable treatment option."

A brief abstract containing a portion of the NARCOMS survey findings was submitted to ECTRIMS in May 2011 and is currently available for viewing at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=136977&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900

The full poster highlighting key findings from the NARCOMS survey presented at the Congress is expected to be available for viewing on the ECTRIMS website within the next 10 business days at: http://www.ectrims.eu/conferences.htm.  

About H.P. Acthar® Gel

H.P. Acthar® Gel is a natural adrenocorticotropic hormone (ACTH) designed to provide a prolonged release after intramuscular or subcutaneous injection. Acthar is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders. For more information, please visit www.acthar.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders.  The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes
2. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
3. PDI Announces Contract Extension With Revenue Value of Approximately $23 Million
4. Unilife COO Makes Open Market Purchase of Approximately $250,000 in Companys Publicly Traded Shares
5. Accuray to Acquire TomoTherapy for Approximately $277 Million in Cash and Stock
6. Court Grants Preliminary Approval to Class Action Settlement that Provides Benefits Of Approximately $20 Million to Healthcare Providers that Purchased a SS1 Before January 1, 2009
7. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
8. HA&W Obtains Approximately $2 M in Credits and Cash Grants for Clients Through the Therapeutic Discovery Project Program
9. The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019
10. Consumer Reports Flu Poll: Approximately Three Out of 10 Health Care Workers Living in a Bubble, Not Getting Flu Vaccine
11. The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):